Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium channel protein type 8 subunit alpha (NaV1.6), encoded by the SCN8A gene, is a major voltage-gated sodium channel highly concentrated at the axon initial segment and nodes of Ranvier in mature central nervous system neurons. It plays a critical role in the initiation and propagation of action potentials, as well as driving repetitive neuronal firing. While NaV1.6 primarily conducts a rapid transient sodium current, it also generates a small, non-inactivating late or persistent sodium current (INaP).
Under pathological conditions, such as gain-of-function mutations in SCN8A, this persistent current is abnormally elevated, leading to neuronal hyperexcitability, repetitive firing, and hypersynchrony. This aberrant activity is a key driver of developmental and epileptic encephalopathies (SCN8A-DEE) and other severe seizure disorders. Consequently, selectively targeting the late/persistent sodium current of NaV1.6 has emerged as a promising precision medicine strategy. Novel therapeutic agents, such as relutrigine (PRAX-562) and zandatrigine (NBI-921352), are designed to preferentially inhibit this persistent current and stabilize the inactivated state of the channel, thereby dampening pathological hyperexcitability while sparing normal transient currents and avoiding off-target effects on other sodium channel isoforms like NaV1.1.
Inhibition of the late/persistent sodium current (INaP) and stabilization of the inactivated state of the NaV1.6 channel, reducing neuronal hyperexcitability and repetitive action potential firing.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium channel protein type 8 subunit alpha (NaV1.6).